NYSE:ABBV 6 February 2026

AbbVie beats analyst estimates and posts one-day value jump bigger than Apogee deal size

AbbVie Inc. jumped about $17.8 billion in market cap Thursday, outpacing the value of the deal that’s driving a fresh look at the drugmaker from investors. Shares closed up 3.99% at $261.07 after hitting a 52-week high of $261.64, with the move coming off a $10.01 gain on roughly 1.77 billion shares outstanding.

3 July 2026

Earnings Reports·NASDAQ:APGE·NYSE:ABBV·Stock Market

AbbVie stock run lifts pricing on $10.9 billion Apogee deal to six times cost

U.S. cash equities didn’t trade Sunday, so AbbVie’s most recent close is Friday at $253.35. That’s a 4.2% gain for the day and up 17.0% since June 18, which was the last session ahead of the Juneteenth break and before AbbVie’s deal week kicked off.

29 June 2026

NASDAQ:APGE·NYSE:ABBV·Pharmaceutical Industry·Stock Market

AbbVie grabs Apogee in $10.9 billion deal as buyouts speed up

AbbVie (NYSE:ABBV) jumps $18 billion Friday, beats Apogee as Skyrizi FDA decision comes Monday

U.S. equity markets were closed for the weekend, so the main takeaway on AbbVie Inc. last week wasn’t limited to the Apogee deal. Investors saw fresh market value assigned to that deal as shares swung again Friday.

27 June 2026

NASDAQ:APGE·NYSE:ABBV·Stock Market

Alphabet rout dents Nasdaq, oil slide gives Dow a lift

Alphabet weighed on U.S. stocks Monday, sending indexes in different directions. The S&P 500 slipped 0.48% to 7,464.36 and the Nasdaq Composite fell 1.41% to 26,143.95. The Dow Jones Industrial Average managed a 0.12% gain to 51,628.79, according to LSEG data on Reuters.

22 June 2026

Nasdaq·NASDAQ:AMZN·NASDAQ:APGE·NASDAQ:GOOGL·NASDAQ:META·NASDAQ:MSFT·NASDAQ:MU·NASDAQ:SPCX·NYSE:ABBV·Oil Prices·Stock Market

AbbVie grabs Apogee in $10.9 billion deal as buyouts speed up

AbbVie said Monday it will buy Apogee Therapeutics for $10.9 billion in cash, picking up a late-stage eczema drug in what would be its biggest deal in over five years. The $135.11 per share offer is about 49% over Apogee’s June 18 close. Both companies’ boards signed off, aiming to wrap up the deal in the third quarter.

22 June 2026

NASDAQ:APGE·NYSE:ABBV·Pharmaceuticals·Stock Market

Apogee Therapeutics (NASDAQ:APGE) stock jumps on AbbVie’s $10.9 billion cash takeover

Apogee Therapeutics shares surged on Monday after AbbVie agreed to acquire the biotech company for $10.9 billion in cash, giving the U.S. drugmaker control of a long-acting immunology drug candidate aimed at eczema and asthma. Apogee was recently trading at $132.69, up about 47%, against AbbVie’s $135.11-a-share offer.

22 June 2026

NASDAQ:APGE·NYSE:ABBV·Pharmaceutical Industry·Stock Market

AbbVie moves to acquire Apogee in $10.9 billion bet on immunology

AbbVie said Monday it’s buying Apogee Therapeutics for $10.9 billion in cash, making this its largest deal since 2019. The company is looking to strengthen its immunology pipeline with Apogee’s long-acting immune-disease drugs. AbbVie and Apogee put out a joint release on the agreement, according to a securities filing. They expect the deal to close in the third quarter of 2026.

22 June 2026

Biotechnology·NYSE:ABBV·Pharmaceuticals

AbbVie-Apogee deal on radar for US healthcare stocks next week

Healthcare stocks in the U.S. could move Monday after a report said AbbVie is nearing a $10.9 billion cash takeover of Apogee Therapeutics. That price would be about 60% over where Apogee ended Thursday. Neither company has confirmed a deal.

21 June 2026

NASDAQ:APOG·NYSE:ABBV·Stock Market

AbbVie Shares Edge Up Ahead Of Holiday On Pipeline News

AbbVie Inc. shares climbed ahead of the U.S. holiday weekend, lifted by a stronger market and several drug-pipeline updates that gave investors new info before cancer meetings next week.

23 May 2026

NYSE:ABBV·Stock Market

Oruka Therapeutics Stock Surges After Psoriasis Drug Data as Biotech Seeks $500 Million

Oruka Therapeutics jumped to secure $500 million through stock and pre-funded warrants Monday, following a spike in its shares after interim results from its investigational psoriasis treatment. The surge also sparked new comparisons to big-name drugs from AbbVie and UCB.

27 April 2026

EBR:UCB·NYSE:ABBV·Pharmaceutical Industry·Stock Market

SCHD Draws Fresh Attention After New Dividend and 2026 Reconstitution

The Schwab U.S. Dividend Equity ETF is back in focus, with a new quarterly payout and a March reshuffling of its holdings putting dividend strategies back in the spotlight during uncertain times. SCHD hovered near $30.57 late Monday morning in New York.

6 April 2026

Dividend Investing·ETFs·NASDAQ:CSCO·NYSE:ABBV·NYSE:ABT·NYSE:COP·NYSE:CVX·NYSE:PG·NYSE:UNH·NYSE:VLO·Portfolio Management·Stock Market

AbbVie Obesity Drug ABBV-295 Hits Up to 9.8% Weight Loss in Early Trial

AbbVie said on Monday its experimental obesity drug ABBV-295 helped adults lose up to 9.79% of their body weight in 12 weeks in an early-stage study, giving the drugmaker its clearest sign yet that it may have a contender in a market led by Eli Lilly and Novo Nordisk. The company said no serious adverse events were reported.

10 March 2026

Health News·NYSE:ABBV·NYSE:LLY·NYSE:NVO·Pharmaceuticals

AbbVie stock price jumps 3% into weekend as $8 billion bond sale nears settlement

AbbVie Inc shares jumped 3.29% to close at $232.08 on Friday, bucking a three-day slide and outperforming the wider market slump. The S&P 500 lost 0.43%, Dow shed 1.05%. AbbVie not only broke its own losing streak but also left Johnson & Johnson, Pfizer, and Amgen trailing behind.

28 February 2026

NYSE:ABBV·Pharmaceutical Industry·Stock Market

AbbVie stock set for $1.73 dividend as ABBV heads into Tuesday’s reopen

AbbVie finished Friday at $231.50 per share, gaining 1.8%. U.S. equity trading paused Monday for Washington’s Birthday, with the New York Stock Exchange closed.

16 February 2026

Dividends·NYSE:ABBV·Pharmaceutical Industry·Stock Market

AbbVie stock ends higher Friday; what traders watch for ABBV after the Presidents Day break

AbbVie Inc finished Friday at $231.50, up 1.8%. The stock moved between $227.33 and $234.69 over the session.

15 February 2026

NYSE:ABBV·Pharmaceuticals·Stock Market

AbbVie stock price rises as analysts reset targets and Wall Street waits on delayed jobs data

AbbVie Inc climbed 0.7% to $224.83 in early afternoon trading Tuesday, sticking near its session peak. Shares moved in a narrow band, fluctuating between $223.00 and $225.78.

10 February 2026

NYSE:ABBV·Pharmaceuticals·Stock Market

AbbVie stock price closes higher on Moody’s upgrade — what ABBV bulls and bears watch next

AbbVie Inc finished Friday’s session 2.0% higher at $223.43, notching a better gain than the broader U.S. stock market and staying in step with the rally among major pharma names.

8 February 2026

NYSE:ABBV·Pharmaceuticals·Stock Market

AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next

AbbVie finished Friday’s session 2% higher at $223.43, notching a second day in the green while U.S. equities climbed. The stock remains about 9% shy of its 52-week high. Trading volume landed slightly below its recent average.

7 February 2026

Earnings Reports·NYSE:ABBV·Pharmaceuticals·Stock Market

AbbVie stock rises as investors re-rank Rinvoq and Skyrizi after earnings jolt

AbbVie shares rose $4.43, or about 2%, to $223.45 in midday trading on Friday, steadying after a choppy week for large drugmakers. The stock traded between $218.51 and $225.81 earlier in the session.

6 February 2026

Earnings Reports·NYSE:ABBV·Pharmaceuticals·Stock Market

AbbVie stock ticks higher after hours as traders digest 2026 outlook after Rinvoq miss

AbbVie Inc shares climbed roughly 0.7% to $219.02 in after-hours trading Thursday, following an intraday range between $214.27 and $221.00.

6 February 2026

Earnings Reports·NYSE:ABBV·Pharmaceuticals·Stock Market

NYSE:ABBV 6 February 2026 - 3 July 2026